

Section 1.	Identifying Inform	nation				
1. Given Name (Fi Tatiana	rst Name)	2. Surname (Last Name) Karakasheva	3. Date 19-January-2018			
4. Are you the corresponding author?		Yes V No	Corresponding Author's Name Anil K. Rustgi			
5. Manuscript Title CD38+ M-MDSC		es a subset of advanced co	olorectal cancer patients			
6. Manuscript Ide 97022-INS-CMEI	ntifying Number (if you kr D-1	now it)				
			-			
Section 2.	The Work Under C	onsideration for Public	cation			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No						
Section 3.	Relevant financial	activities outside the s	submitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo						
Section 4.	Intellectual Prope	rty Patents & Copyric	phts			
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No			

Karakasheva 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Karakasheva	has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Karakasheva 3



Section 1.	Identifying Inform	nation				
1. Given Name (Fi George	rst Name)	2. Surname (Last Name) Dominguez	3. Date 19-January-2018			
4. Are you the corresponding author?		Yes 🗸 No	Corresponding Author's Name Anil K Rustgi			
5. Manuscript Title CD38+ M-MDSC		es a subset of advanced co	lorectal cancer patients			
6. Manuscript Ide	ntifying Number (if you kr	now it)				
Section 2.	The Work Under C	onsideration for Public	ation			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No						
Section 3.	Relevant financial	activities outside the s	ubmitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo						
Section 4.	Intellectual Prope	rty Patents & Copyric	hts			
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No			

Dominguez 2



Section 5.	
Relationships not covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the potentially influencing, what you wrote in the submitted work?	e appearance of
Yes, the following relationships/conditions/circumstances are present (explain below):	
No other relationships/conditions/circumstances that present a potential conflict of interest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their On occasion, journals may ask authors to disclose further information about reported relationships.	^r disclosure statements.
Section 6. Disclosure Statement	
Based on the above disclosures, this form will automatically generate a disclosure statement, which will below.	appear in the box
Dr. Dominguez has nothing to disclose.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Dominguez 3



Section 1.	Identifying Inform	nation					
1. Given Name (Fi Eric		2. Surname (Last Name) Lin	3. Date 19-January-2018				
4. Are you the corresponding author?		Yes 🗸 No	Corresponding Author's Name Anil K. Rustgi				
5. Manuscript Title CD38+ M-MDSC		es a subset of advanced co	lorectal cancer patients				
6. Manuscript Ide 97022-INS-CMEI	ntifying Number (if you kr D-1	now it)					
			-				
Section 2.	The Work Under C	onsideration for Public	ation				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?							
Are there any rei	Are there any relevant conflicts of interest? Yes V No						
Section 3.	Delevent finen siel	activities outside the s	ula maissa ad una ula				
_	Relevant financial	activities outside the s	ubmitted work.				
of compensation	n) with entities as descr	ibed in the instructions. Us	ether you have financial relationships (regardless of amor se one line for each entity; add as many lines as you need e present during the 36 months prior to publication .				
Are there any relevant conflicts of interest? Yes V No							
Section 4.	Intellectual Prope	rty Patents & Copyric	hts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Lin 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Lin has nothi	ing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lin 3



Section 1.	Identifying Inform	nation			
1. Given Name (Fi Jae	. , ,	2. Surname (Last Name) Lee	3. Date 19-January-2018		
4. Are you the corresponding author?		Yes V No	Corresponding Author's Name Anil K. Rustgi		
5. Manuscript Title CD38+ M-MDSC		es a subset of advanced co	lorectal cancer patients		
6. Manuscript Ide 97022-INS-CMEI	ntifying Number (if you kr D-1	now it)			
Section 2.	The Work Under Co	onsideration for Public	cation		
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No					
Section 3.	Relevant financial	activities outside the s	submitted work.		
of compensatior clicking the "Adc Are there any rel	the appropriate boxes i n) with entities as descri	n the table to indicate who ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication .		
Section 4.	Intellectual Proper	ty Patents & Copyric	ghts		
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No		

Lee 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Lee has noth	ing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lee 3



Section 1. Identifying Info	rmation					
1. Given Name (First Name) Gregory	2. Surname (Last Name) Beatty	3. Date 19-January-2018				
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name				
5. Manuscript Title CD38+ M-MDSC expansion character	izes a subset of advanced co	olorectal cancer patients				
6. Manuscript Identifying Number (if you 97022-INS-CMED-1	know it)	_				
Section 2. The Work Under	Consideration for Public	cation				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No						
Section 3. Relevant financia	al activities outside the s	submitted work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes V No						
Section 4. Intellectual Prop	erty Patents & Copyric	ghts				
Do you have any patents, whether pla	anned, pending or issued, br	roadly relevant to the work? Yes V No				

Beatty 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Beatty has no	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Beatty 3



Section 1. Identifying Inform	nation								
1. Given Name (First Name) A Kate	2. Surname (Last Name) Sasser	3. Date 19-January-2018							
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Anil K Rustgi							
5. Manuscript Title CD38+ mMDSC expansion characterize	_								
6. Manuscript Identifying Number (if you kr	now it)								
Section 2. The Work Under Co	onsideration for Publi	cation							
any aspect of the submitted work (including statistical analysis, etc.)?	Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No								
Section 3. Relevant financial	activities outside the	submitted work.							
of compensation) with entities as descri	ibed in the instructions. Use port relationships that we lest?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.							
Name of Entity	Grant? Personal Nor	upport? Other • Comments							
Janssen		previous employee							
Genmab		current employee							
Section 4. Intellectual Proper	rty Patents & Copyri	ghts							
Do you have any patents, whether plan If yes, please fill out the appropriate info Excess rows can be removed by pressin	ormation below. If you hav	roadly relevant to the work? Yes No e more than one entity press the "ADD" button to add a row.							

Sasser 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee ?	Comments	
Targeting of CD38 positive immune suppressive populations with Daratumumah	/						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh No other relationships/cond	•			•	•	st	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							ients.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	II automa	atically gene	erate a disclo	sure statement, v	vhich will appear in the box	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Sasser 3



Section 1. Identifying Inform	nation	
Given Name (First Name) Dmitry	2. Surname (Last Name) Gabrilovich	3. Date 19-January-2018
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name A. Rustgi
5. Manuscript Title CD38-MDSC-CRC		
6. Manuscript Identifying Number (if you kr 97022-INS-CMED-1	now it)	_
Section 2.		
The Work Under Co	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intere	est? ✓ Yes No	
If yes, please fill out the appropriate info	ormation below.	
Name of Entity	Grant? Personal Nor	on-Financial Other? Comments
Reata Pharmaceutical	V	
Janssen	✓	
Syndax		
Section 4. Intellectual Proper	rty Patents & Copyrig	uhts
intellectual Propel	rty - ratents & copyrig	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Gabrilovich 2



Section 5. Polotic achieves de la constant de la co
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Gabrilovich reports grants from Reata Pharmaceutical, grants from Janssen, grants from Syndax, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Gabrilovich 3



Section 1.	Identifying Inform	ation		
1. Given Name (Firs Anil	it Name)	2. Surname (Last Name) Rustgi		3. Date 19-January-2018
4. Are you the corre	esponding author?	✓ Yes No		
5. Manuscript Title CD38+ M-MDSC 6	expansion characterize	es a subset of advanced color	ectal cancer patients	
6. Manuscript Ident 97022-INS-CMED-	ifying Number (if you kn -1	ow it)		
Section 2.	The Work Under Co	onsideration for Publicati	on	
any aspect of the su statistical analysis, e	bmitted work (including	but not limited to grants, data m		ommercial, private foundation, etc.) for esign, manuscript preparation,
Section 3.	Relevant financial :	activities outside the sub	mitted work	
Place a check in th of compensation) clicking the "Add - Are there any rele	ne appropriate boxes in with entities as descri	n the table to indicate whether bed in the instructions. Use o port relationships that were p	er you have financial rel ne line for each entity; a	lationships (regardless of amount add as many lines as you need by nonths prior to publication.
Section 4.	Intellectual Proper	ty Patents & Copyright	5	
Do you have any p	patents, whether plant	ned, pending or issued, broad	ly relevant to the work	? Yes 🗸 No

Rustgi 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Rustgi has no	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rustgi 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The

patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Hashimoto 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Ayumi	2. Surname (Last Name) Hashimoto	3. Date 23-January-2018
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Anil Rustgi
5. Manuscript Title CD38+ M-MDSC expansion characterize	s a subset of advanced co	olorectal cancer patients
6. Manuscript Identifying Number (if you kn	ow it)	
		_
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da st? Yes No rmation below. If you have	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial Other? Comments
Daiichi Sankyo Co., Ltd.	✓	
Section 3. Relevant financial a	activities outside the s	submitted work.
of compensation) with entities as descril	bed in the instructions. Us port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plann	ned, pending or issued, br	roadly relevant to the work? Yes V No

Hashimoto 2



Section 5.
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hashimoto reports personal fees from Daiichi Sankyo Co., Ltd., during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hashimoto 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

- Identifying information.
- 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The

patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Chiu 1



Section 1. Identifying Inform	ation	
Given Name (First Name) Christopher	2. Surname (Last Name) Chiu	3. Date 21-January-2018
4. Are you the corresponding author?	Yes No	Corresponding Author's Name Anil K. Rustgi
Manuscript TitleCD38+ M-MDSC expansion characterize	es a subset of advanced co	lorectal cancer patients
6. Manuscript Identifying Number (if you kn	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Use port relationships that we est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Name of Entity	Grant? Personal Fees? S	n-Financial other? Comments
Janssen Pharmaceutica l s		Employee
	ty Patents & Copyrig	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Chiu 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Chiu reports	other from Janssen Pharmaceuticals, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Chiu 3

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	-
		(b) Provide in the abstract an informative and balanced summary of what	3
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6, 10
Setting	5	Describe the setting, locations, and relevant dates, including periods of	10
C		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	10
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	Not
Variables	7	unexposed Clearly define all outcomes, exposures, predictors, potential confounders,	appl. 6, 10
variables	,	and effect modifiers. Give diagnostic criteria, if applicable	0, 10
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	10, 11
measurement	O	assessment (measurement). Describe comparability of assessment methods	10, 11
measurement		if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	11
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	10,11
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	10,11
		confounding (b) Describe any methods used to everying subgroups and interactions	NI A
		(b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed	NA 8-9
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
D 14		(E) Describe any sensitivity analyses	IVA
Results	12*	(a) Papart numbers of individuals at each stage of study, ag numbers	10
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in	10
		the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	Fig. 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	19,
<u>r</u>		social) and information on exposures and potential confounders	Tab.S1
		(b) Indicate number of participants with missing data for each variable of	Tab.S1
		interest	
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	11
		estimates and their precision (eg, 95% confidence interval). Make clear	

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8,9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.